Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration

Summary

CD146, a novel cell adhesion molecule localized at the endothelial junction, is involved in the control of cell-cell cohesion. It is found as a soluble form in conditioned medium of cultured endothelial cells. We developed an ELISA and report for the first time the presence of a soluble form of CD146 (sCD146) in the plasma of healthy subjects. Mean sCD146 values (260 ± 60 ng/ml) were higher in subjects over 50 years and in men. We therefore investigated sCD146 values in patients with chronic renal failure (CRF), a clinical setting associated with junctional alterations. A significant increase in sCD146 was found in patients with CRF matched with controls (457 ± 181 ng/ml versus 288 ± 82 ng/ml respectively, p<0.0001). This increase was corroborated by increased endothelial expression of CD146 on kidney biopsies from patients with CRF. In contrast, in patients with CRF no modulation was observed for the soluble and cell-associated form of CD31, another junctional molecule. Together these data indicate that sCD146 circulates in the plasma of healthy subjects. Modifications of its basal levels could reflect alterations of junctional functions such as vascular permeability.

Keywords

CD146 - endothelial cells - endothelial junction - soluble endothelial marker - chronic renal failure

• References

• 1 Cines D. et al Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61.
• 2 Hormia M. et al Endotheliuman organized monolayer of highly specialized cells. Med Biol 1998; 64: 247-66.
• 3 Vesterweber D. Molecular mechanisms that control endothelial cell contacts. J Pathol 2000; 190: 281-91.
• 4 Dejana E. et al Molecular organization and functional regulation of cell to cell junction in endothelium. Thromb Haemost 1995; 74: 309-12.
• 5 Dejana E. Endothelial adherens junctions: implications in the control of vascular permeability and angiogenesis. J Clin Invest 1996; 98: 1949-53.
• 6 Breviario F. et al Functional properties of human vascular endothelial cadherin (7B4/ cadherin-5), an endothelium-specific cadherin. Arterioscler Thromb Vasc Biol 1995; 15: 1229-39.
• 7 Albelda SM. et al Molecular and cellular properties of PECAM-1 (endoCAM/CD31):a novel vascular cell-to-cell adhesion molecule. J Cell Biol 1991; 114: 1059-68.
• 8 Bardin N. et al Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. Blood 2001; 98: 3677-84.
• 9 Bardin N. et al Identification of the S-Endo 1 endothelial-associated antigen. Biochem Biophys Res Commun 1996; 218: 210-6.
• 10 Bardin N. et al S-Endo 1, a pan-endothelial monoclonal antibody recognizing a novel human endothelial antigen. Tissue Antigens 1996; 548: 531-9.
• 11 Lehmann JM. et al MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 1989; 86: 9891-5.
• 12 Solovey AN. et al Identification and functional assessment of endothelial P1H12. J Lab Clin Med 2001; 138: 322-31.
• 13 Shih IM. The role of CD146 (Mel-CAM) in biology and pathology. J Pathol 1999; 189: 4-11. Review
• 14 Anfosso F. et al Activation of human endothelial cells via S-endo-1 antigen (CD146) stimulates the tyrosine phosphorylation of focal adhesion kinase p125(FAK). J Biol Chem 1998; 273: 26852-6.
• 15 Anfosso F. et al Outside-in signaling pathway linked to CD146 engagement in human endothelial cells. J Biol Chem 2001; 276: 1564-9.
• 16 Bardin N. et al CD 146:biosynthesis and production of a soluble form in human cultured endothelial cells. FEBS Lett 1998; 421: 12-4.
• 17 Wheeler DC. Cardiovascular disease in patients with chronic renal failure. Lancet 1996; 348: 1673-4.
• 18 London GM. et al Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997; 51: 1678-1795.
• 19 Lindner A. et al Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701.
• 20 Thambyrajah J. et al Abnormalities of endothelial function in patients with predialysis renal Failure. Heart 2000; 83: 205-9.
• 21 Pannier B. et al Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease. Kidney Int 2000; 57: 1091-9.
• 22 Segarra A. et al Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients:biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol 2001; 12: 1255-63.
• 23 Bonomini M. et al Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients. Nephron 1998; 79: 399-407.
• 24 Jacobson SH. et al Correlation between soluble markers of endothelial dysfunction in patients with renal failure. Am J Nephrol 2002; 22: 42-7.
• 25 Evan I G. et al Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol 1985; 5 (12) 3610-6.
• 26 Dignat-George F. et al. S-Endo/Muc18 preCD workshop report. In leucocyte Typing. VI New York and London: Garland Publishing, Inc.; Kishimoto T.. et al. 1997: 755-9.
• 27 Nash MC. et al Normal levels of soluble E-selectin, soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease with age. Clin Exp Immunol 1996; 103: 167-70.
• 28 Marin J. et al Age-related changes in vascular responses. Exp Gerontol 1999; 34 (04) 503-2. Review
• 29 Otero K. et al Albumin-derived advanced glycation end-products trigger the disruption of the vascular endothelial cadherin complex in cultured human and murine endothelial cells. Biochem J 2001; 359: 567-74.
• 30 Belmin J. et al Age-related changes in endothelial permeability and distribution volume of albumin in rat aorta. Am J Physiol 1993; 264: H679-85.
• 31 Miller VM. Gender and vascular reactivity. Lupus 1999; 8: 409-15.
• 32 Teede H. et al. Cardiovascular effects of sex hormones. Clin Sci (Lond) 1999; 97: 1-3.
• 33 Harper SJ. et al Human uremic plasma increases microvascular permeability to water and proteins in vivo. Kidney Int 2002; 61: 1416-22.
• 34 Combet S. et al Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 2001; 12: 2146-5.
• 35 Heidland A. et al Release of granulocyte neutral proteinases in patients with acute and chronic renal failure. Adv Exp Med Biol 1984; 167: 417-31.
• 36 Hermant B. et al. Identification of proteases involved in the proteolysis of vascular endothelium cadherin during neutrophil transmigration. J Biol Chem 2003; 278: 14002-12.
• 37 Ozaki H. et al. Cutting edge: combined treatment of TNF-alpha and IFN-gamma causes redistribution of junctional adhesion molecule in human endothelial cells. J Immunol 1999; 163: 553-7.
• 38 Briscoe DM. et al Expression of vascular cell adhesion molecule-1 in human renal allo-grafts. J Am Soc Nephrol 1992; 3: 1180-5.
• 39 Abbate M. et al Expression of NCAM recapitulates tubulogenic development in kidneys recovering from acute ischemia. Am J Physiol 1999; 277: F454-63.
• 40 Daniel L. et al Tubular lesions and tubular cell adhesion molecules for the prognosis of lupus nephritis. Kidney Int 2001; 60: 2215-21.